You are here

peanut allergy

Aimmune's peanut allergy drug secures FDA panel support, along with criticism

Aimmune's peanut allergy drug secures FDA panel support, along with criticism

Biopharma Dive

Flag link:

An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening

An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening

Stat

advisory panels

Aimmune Therapeutics

Flag link:

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

Endpoints

Flag link:

DBV Technologies Resubmits BLA for Peanut Allergy Treatment

DBV Technologies Resubmits BLA for Peanut Allergy Treatment

BioSpace

DBV Technologies

Flag link:

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

Endpoints

Aimmune Therapeutics

DBV Technologies

Flag link:

Vedanta Biosciences enrolls first patient in VE416 phase 1b/2 food allergy clinical study

Vedanta Biosciences enrolls first patient in VE416 phase 1b/2 food allergy clinical study

Pharmaceutical Business Review

Vedanta Biosciences

clinical trials

Flag link:

FDA schedules Aimmune's peanut allergy drug for September expert review

FDA schedules Aimmune's peanut allergy drug for September expert review

Biopharma Dive

Aimmune Therapeutics

Flag link:

Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

Endpoints

Flag link:

4 Blockbuster Drug Launches to Watch in 2019

4 Blockbuster Drug Launches to Watch in 2019

Motley Fool

Alexion Pharmaceuticals

Aimmune Therapeutics

rheumatoid arthritis

Flag link:

Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear

Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear

BioSpace

Aimmune Therapeutics

Flag link:

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

Xconomy

DBV Technologies

Flag link:

Aimmune says shutdown blocks peanut allergy drug review

Aimmune says shutdown blocks peanut allergy drug review

Fierce Biotech

Aimmune Therapeutics

government shutdown

Flag link:

DBV Technologies pulls peanut allergy treatment from FDA review

DBV Technologies pulls peanut allergy treatment from FDA review

Stat

DBV Technologies

Flag link:

Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts

Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts

Endpoints

Aimmune Therapeutics

Flag link:

Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies

Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies

Endpoints

Aimmune Therapeutics

Flag link:

AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool

AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool

Motley Fool

Flag link:

AnaptysBio plans phase 2b peanut allergy trial after taking positives from POC data

AnaptysBio plans phase 2b peanut allergy trial after taking positives from POC data

Fierce Biotech

clinical trials

Flag link:

Peanut allergy therapy scores trial win, putting it in line to possibly become first protective treatment

Peanut allergy therapy scores trial win, putting it in line to possibly become first protective treatment

Stat

clinical trials

Flag link:

DBV climbs as peanut allergy safety data come in clean

DBV climbs as peanut allergy safety data come in clean

Fierce Biotech

DBV Technologies

Flag link:

A new peanut allergy vaccine failed in a trial, but the company wants it approved anyway

A new peanut allergy vaccine failed in a trial, but the company wants it approved anyway

Stat

DBV Technologies

Flag link:

Pages